BIVV001

Unassigned

New Medicines

Haemophilia A

Information

New molecular entity
Sanofi
Sanofi

Development and Regulatory status

None
None
Phase III Clinical Trials
Yes

Category

A fully recombinant blood factor, using XTEN technology, that comprises a large polypeptide that inhibits renal clearance and may inhibit receptor mediated clearance for some molecules
It affects 1:4,000 to 1:5,000 live male births worldwide. It is five times as common as haemophilia B [1].
Haemophilia A
Intravenous